ENTA Enanta Pharmaceuticals, Inc.
Healthcare$13.53-3.01%ClosedMarket Cap: $314.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.46
P/S
4.68
EV/EBITDA
-9.78
DCF Value
$-58.72
FCF Yield
-3.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.3%
Operating Margin
-87.2%
Net Margin
-89.6%
ROE
-64.0%
ROA
-19.7%
ROIC
-19.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $17.2M | 93.0% | $-11.9M | $-13.1M | $— | — |
| Q1 null | $18.6M | 100.0% | $-11.3M | $-11.9M | $— | — |
| Q4 null | $15.1M | 100.0% | $-18.4M | $-18.7M | $— | — |
| FY null | $65.3M | 93.0% | $-85.3M | $-81.9M | $— | — |
| Q3 null | $18.3M | 100.0% | $-18.9M | $-18.3M | $— | — |
| Q2 null | $14.9M | 100.0% | $-24.5M | $-22.6M | $— | — |
| Q1 null | $17.0M | 100.0% | $-23.5M | $-22.3M | $— | — |
| Q4 null | $14.6M | 100.0% | $-29.9M | $-28.8M | $— | — |
| FY null | $67.6M | 100.0% | $-121.7M | $-116.0M | $— | — |
| Q3 null | $18.0M | 100.0% | $-24.2M | $-22.7M | $— | — |
| Q2 null | $17.1M | 100.0% | $-32.8M | $-31.2M | $— | — |
| Q1 2024 | $18.0M | 100.0% | $-34.9M | $-33.4M | $-1.58 | — |